T2 Biosystems

T2 Biosystems EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of T2 Biosystems (TTOO) as of Oct 16, 2026 is -43.83 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -54.93 M USD — a change of -20.20% (higher).

EBITDA

-43.83 MUSD

YoY

-20.20%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of T2 Biosystems is 2023 -43.83 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of T2 Biosystems was 2022 -54.93 M USD. It decreases by -20.20% higher compared to the previous year.

The T2 Biosystems EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2016
-50.71 M USD
Jan 1, 2017
-53.52 M USD
Jan 1, 2018
-44.47 M USD
Jan 1, 2019
-51.94 M USD
Jan 1, 2020
-41.29 M USD
Jan 1, 2021
-43.67 M USD
Jan 1, 2022
-54.93 M USD
Jan 1, 2023
-43.83 M USD
The T2 Biosystems EBITDA history
YEAREBITDAYoY
-43.83 MUSD-20.20%
-54.93 MUSD+25.79%
-43.67 MUSD+5.74%
-41.29 MUSD-20.50%
-51.94 MUSD+16.80%
-44.47 MUSD-16.91%
-53.52 MUSD+5.55%
-50.71 MUSD+16.88%
-43.38 MUSD+41.40%
-30.68 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

T2 Biosystems Stock analysis

What does T2 Biosystems do? T2 Biosystems Inc, headquartered in Lexington, Massachusetts, operates in the Health Care sector, specifically within Biotechnology. The company develops the T2 Magnetic Resonance platform (T2MR), which detects pathogens, biomarkers, and abnormalities in unpurified patient samples like whole blood and urine. Its technology enables detection at one colony forming unit per milliliter (CFU/mL) and targets sepsis, hemostasis, and Lyme disease. T2 Biosystems offers the T2Dx Instrument and T2Candida Panel for diagnostic use. T2 Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about T2 Biosystems stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of T2 Biosystems is -43.83 M USD in 2023.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of T2 Biosystems changed from -54.93 M USD to -43.83 M USD, representing a -20.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) T2 Biosystems since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s T2 Biosystems historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — T2 Biosystems

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — T2 Biosystems